These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
289 related articles for article (PubMed ID: 31049586)
1. Intravenous colistin use for infections due to MDR Gram-negative bacilli in critically ill paediatric patients: a systematic review and meta-analysis. Karageorgos SA; Bassiri H; Siakallis G; Miligkos M; Tsioutis C J Antimicrob Chemother; 2019 Sep; 74(9):2497-2506. PubMed ID: 31049586 [TBL] [Abstract][Full Text] [Related]
2. Intravenous combined with aerosolised polymyxin versus intravenous polymyxin alone in the treatment of pneumonia caused by multidrug-resistant pathogens: a systematic review and meta-analysis. Liu D; Zhang J; Liu HX; Zhu YG; Qu JM Int J Antimicrob Agents; 2015 Dec; 46(6):603-9. PubMed ID: 26607337 [TBL] [Abstract][Full Text] [Related]
3. Clinical experience of colistin-glycopeptide combination in critically ill patients infected with Gram-negative bacteria. Petrosillo N; Giannella M; Antonelli M; Antonini M; Barsic B; Belancic L; Inkaya A C; De Pascale G; Grilli E; Tumbarello M; Akova M Antimicrob Agents Chemother; 2014; 58(2):851-8. PubMed ID: 24277037 [TBL] [Abstract][Full Text] [Related]
4. Differences in pharmacokinetics and pharmacodynamics of colistimethate sodium (CMS) and colistin between three different CMS dosage regimens in a critically ill patient infected by a multidrug-resistant Acinetobacter baumannii. Luque S; Grau S; Valle M; Sorlí L; Horcajada JP; Segura C; Alvarez-Lerma F Int J Antimicrob Agents; 2013 Aug; 42(2):178-81. PubMed ID: 23769664 [TBL] [Abstract][Full Text] [Related]
6. Intravenous colistin sulfate: a rarely used form of polymyxin E for the treatment of severe multidrug-resistant Gram-negative bacterial infections. Huang J; Tang YQ; Sun JY Scand J Infect Dis; 2010 Apr; 42(4):260-5. PubMed ID: 20085424 [TBL] [Abstract][Full Text] [Related]
7. Inhaled colistin monotherapy for respiratory tract infections in adults without cystic fibrosis: a systematic review and meta-analysis. Vardakas KZ; Voulgaris GL; Samonis G; Falagas ME Int J Antimicrob Agents; 2018 Jan; 51(1):1-9. PubMed ID: 28669836 [TBL] [Abstract][Full Text] [Related]
8. Intravenous colistimethate (colistin) use in critically ill children without cystic fibrosis. Falagas ME; Sideri G; Vouloumanou EK; Papadatos JH; Kafetzis DA Pediatr Infect Dis J; 2009 Feb; 28(2):123-7. PubMed ID: 19116601 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, Thailand. Koomanachai P; Tiengrim S; Kiratisin P; Thamlikitkul V Int J Infect Dis; 2007 Sep; 11(5):402-6. PubMed ID: 17291803 [TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infections. Cheng CY; Sheng WH; Wang JT; Chen YC; Chang SC Int J Antimicrob Agents; 2010 Mar; 35(3):297-300. PubMed ID: 20045293 [TBL] [Abstract][Full Text] [Related]
11. Steady-state pharmacokinetic and pharmacodynamic profiling of colistin in critically ill patients with multi-drug-resistant gram-negative bacterial infections, along with differences in clinical, microbiological and safety outcome. Ram K; Sheikh S; Bhati RK; Tripathi CD; Suri JC; Meshram GG Basic Clin Pharmacol Toxicol; 2021 Jan; 128(1):128-140. PubMed ID: 33245629 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of low-dose colistin in the treatment for infections caused by multidrug-resistant gram-negative bacteria. Zaidi ST; Al Omran S; Al Aithan AS; Al Sultan M J Clin Pharm Ther; 2014 Jun; 39(3):272-6. PubMed ID: 24593154 [TBL] [Abstract][Full Text] [Related]
13. Effectiveness and nephrotoxicity of intravenous colistin for treatment of patients with infections due to polymyxin-only-susceptible (POS) gram-negative bacteria. Falagas ME; Kasiakou SK; Kofteridis DP; Roditakis G; Samonis G Eur J Clin Microbiol Infect Dis; 2006 Sep; 25(9):596-9. PubMed ID: 16955249 [TBL] [Abstract][Full Text] [Related]
14. Greater optimisation of pharmacokinetic/pharmacodynamic parameters through a loading dose of intravenous colistin in paediatric patients. Wacharachaisurapol N; Phasomsap C; Sukkummee W; Phaisal W; Chanakul A; Wittayalertpanya S; Chariyavilaskul P; Puthanakit T Int J Antimicrob Agents; 2020 Jun; 55(6):105940. PubMed ID: 32179149 [TBL] [Abstract][Full Text] [Related]
15. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Kasiakou SK; Michalopoulos A; Soteriades ES; Samonis G; Sermaides GJ; Falagas ME Antimicrob Agents Chemother; 2005 Aug; 49(8):3136-46. PubMed ID: 16048915 [TBL] [Abstract][Full Text] [Related]
16. The clinical profile and outcomes of adult patients given intravenous colistin for multidrug-resistant gram negative infections in a Philippine tertiary hospital. Li KL; Abad CLR Int J Infect Dis; 2020 Apr; 93():9-14. PubMed ID: 31978579 [TBL] [Abstract][Full Text] [Related]
17. The evaluation of safety and efficacy of colistin use in pediatric intensive care unit: Results from two reference hospitals and review of literature. Sahbudak Bal Z; Kamit Can F; Yazici P; Berna Anil A; Duyu M; Yilmaz Ciftdogan D; Nisel Yilmaz O; Cilli F; Karapinar B J Infect Chemother; 2018 May; 24(5):370-375. PubMed ID: 29361414 [TBL] [Abstract][Full Text] [Related]